Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Bortezomib in newly diagnosed multiple myeloma around autologous transplant
ACTRN12605000770662Phase 2Completed
- Sponsor
- Royal Adelaide Hospital
- Start
- May 2005
- Modality
- Reversible Covalent Inhibitors → Covalent Small Molecules → Small Molecules
- Countries
- 1
01
Overview
Phase 2, open-label trial of bortezomib in multiple myeloma (MM) (3 arms), sponsored by Royal Adelaide Hospital. Started May 2005; status: completed.
02
Drugs
bortezomib
03
Conditions
multiple myeloma (MM)
Beyond the preview
Go deeper on ACTRN12605000770662.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on ACTRN12605000770662.